Hudock Inc. Sells 727 Shares of Novo Nordisk A/S (NYSE:NVO)

Hudock Inc. reduced its position in Novo Nordisk A/S (NYSE:NVO) by 22.1% during the third quarter, HoldingsChannel.com reports. The firm owned 2,565 shares of the company’s stock after selling 727 shares during the period. Hudock Inc.’s holdings in Novo Nordisk A/S were worth $305,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in NVO. 1620 Investment Advisors Inc. bought a new position in Novo Nordisk A/S in the second quarter worth approximately $25,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S during the second quarter valued at $25,000. Dixon Mitchell Investment Counsel Inc. purchased a new position in shares of Novo Nordisk A/S during the first quarter valued at $26,000. Orion Capital Management LLC bought a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $26,000. Finally, Gilliland Jeter Wealth Management LLC lifted its stake in Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after acquiring an additional 120 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 9th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $144.50.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded up $0.01 during trading on Friday, reaching $113.93. The stock had a trading volume of 879,539 shares, compared to its average volume of 4,270,113. Novo Nordisk A/S has a 1-year low of $92.94 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The business has a fifty day moving average price of $127.52 and a 200-day moving average price of $131.50. The stock has a market cap of $511.26 billion, a PE ratio of 39.02, a PEG ratio of 1.52 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The business had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were given a $0.5126 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 24.66%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.